Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms

References

1. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573–82.10.1200/JCO.2010.29.8711Search in Google Scholar PubMed

2. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009;114:5264–70.10.1182/blood-2009-07-234880Search in Google Scholar PubMed

3. McCann SR, Crampe M, Molloy K, Lawler M. Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci 2005;32:55–61.10.1016/j.transci.2004.10.006Search in Google Scholar PubMed

4. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH. Use of the activating gene mutation of the tyrosine kinase (Val617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007;83:1518–20.10.1097/01.tp.0000263393.65764.f4Search in Google Scholar PubMed

5. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136:745–51.10.1111/j.1365-2141.2007.06497.xSearch in Google Scholar PubMed

6. Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 2012;26:1821–8.10.1038/leu.2012.66Search in Google Scholar PubMed

7. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, et al. Impact of JAK2 V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010;116:3572–81.10.1182/blood-2009-12-260588Search in Google Scholar PubMed

8. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2 V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia 2013 Aug 13. [Epub ahead of print].10.1038/leu.2013.219Search in Google Scholar PubMed PubMed Central

9. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haematologica 2013;98:772–8.10.3324/haematol.2012.076901Search in Google Scholar PubMed PubMed Central

10. Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, et al. JAK2 V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009;113:1866–8.10.1182/blood-2008-11-190975Search in Google Scholar PubMed